Asthma - Epidemiology Forecast to 2029

Asthma - Epidemiology Forecast to 2029



Asthma is a common respiratory condition that affects the lungs. The airways in the lungs narrow and well, causing obstruction to the airflow (CDC, 2013; NHS, 2018). For some people asthma is mild, but in severe cases, people can experience life-threatening asthma attacks (Mayo Clinic, 2018). In most cases, the cause of asthma is unknown, and although there is no cure, medication can help control asthma (CDC, 2013). Asthma can develop at any stage of life. Often, in children, asthma can resolve during their teenage years; however, it is usually a long-term illness, especially if it first develops in adulthood (NHS, 2018).

epidemiologists used age- and sex-specific lifetime diagnosed prevalence rates to forecast the lifetime diagnosed prevalent cases. epidemiologists applied country-specific lifetime diagnosed prevalence rates of asthma, wherever available, to each countrys population to obtain the number of estimated lifetime diagnosed prevalent cases. Lifetime diagnosed prevalent cases were also segmented by severity of asthma.

The following data describes epidemiology of asthma cases. In 2019, the 7MM had 86,751,036 lifetime diagnosed prevalent cases of asthma. This is expected to increase to 89,414,720 cases by 2029, at an Annual Growth Rate (AGR) of 0.31%. The increase is driven by changes in the in the underlying population structure such as aging and population growth in the 7MM. In 2019, intermittent asthma was the most predominant severity in the 7MM. The US had the highest number of lifetime diagnosed prevalent cases of asthma. The development of more effective therapies, particularly for severe persistent and difficult-to-treat patients, would improve quality of life and reduce the frequency with which patients experience symptoms.

Scope

- The Asthma Epidemiology Report provides an overview of the risk factors and global trends of asthma in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- This report also includes a 10-year epidemiological forecast for the following segmentations in all across the 7MM: lifetime diagnosed prevalent cases of asthma; lifetime diagnosed prevalent cases of pancreatic cancer by severity.
- The asthma epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to Buy

The Asthma Epidemiology series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global asthma market.
- Quantify patient populations in the global asthma market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for asthma therapeutics in each of the markets covered.
- Understand magnitude of asthma population by severity.

1


2 Asthma: Executive Summary
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for Asthma (2019-2029)
3.5.1 Lifetime Diagnosed Prevalent Cases of Asthma
3.5.2 Age-Specific Lifetime Diagnosed Prevalent Cases of Asthma
3.5.3 Sex-Specific Lifetime Diagnosed Prevalent Cases of Asthma
3.5.4 Lifetime Diagnosed Prevalent Cases of Asthma by Severity
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of Analysis
3.6.3 Strengths of Analysis
4 Appendix
4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologist
4.2.2 Reviewers
4.2.3 Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head and EVP of Healthcare Operations and Strategy
4.3 About GlobalData
4.4 Contact Us
4.5 Disclaimer

List Of Tables

Table 1: Summary of Newly Added Data Types
Table 2: Summary of Updated Data Types
Table 3: Risk Factors and Comorbidities for Asthma

List Of Figures

Figure 1: 7MM, Lifetime Diagnosed Prevalent Cases of Asthma, N, Both Sexes, All Ages, 2019 and 2029
Figure 2: 7MM, Lifetime Diagnosed Prevalence of Asthma (%), Both Sexes, All Ages, 2009-2019
Figure 3: 7MM, Sources Used for Lifetime Diagnosed Prevalence of Asthma (%)
Figure 4: 7MM, Sources Used for Severity of Asthma (%)
Figure 5: Lifetime Diagnosed Prevalent Cases of Asthma, 7MM, Both Sexes, All Ages, N, 2019
Figure 6: Age-Specific Lifetime Diagnosed Prevalent Cases of Asthma, 7MM, Both Sexes, All Ages, N, 2019
Figure 7: Sex-Specific Lifetime Diagnosed Prevalent Cases of Asthma, 7MM, All Ages, N, 2019
Figure 8: Lifetime Diagnosed Prevalent Cases of Asthma by Severity, 7MM, Both Sexes, All Ages, N, 2019

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available